The diagnostic efficacy of urinary TGF-β1 and VEGF in bladder cancer: Comparison with voided urine cytology

Cancer Biomarkers

Volumn 3, Issue 6, 2007, Pages 275-285

  Eissa, Sanaa ^a   Salem, Ahmed M ^b   Zohny, Samir F ^b   Hegazy, Marwa G A ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b Ain Shams University   (Egypt)

Author keywords

Angiogenesis; Bladder cancer; TGF 1; Urine cytology; VEGF

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; SUPERNATANT; URINARY TRACT DISEASE; URINE CYTOLOGY; URINE SEDIMENT; WESTERN BLOTTING;

EID: 36549031764     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2007-3601     Document Type: Article

References (35)

1. J.R. Benson, Role of transforming growth factor β in breast carcinogenesis, Lancet Oncol 5 (2004), 229-239.
2. W. Bian and Z. Xu, Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma, Int J Urol 14 (2007), 108-111.
3. M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal Biochem 72 (1976), 248-254.
4. M. Burchardt, T. Burchardt, A. Shabsigh, A. De La Taille, M.C. Benson and I. Sawczuk, Current concepts in biomarker technology for bladder cancers, Clin Chem 46 (2000), 595-605.
5. J.H. Choi and S.-G. Chang, Clinical impact of urinary vascular endothelial growth factor (VEGF) in patients with transitional cell carcinoma of the bladder, Korean J Urol 39 (1998), 573-579.
6. J.P. Crew, T. O'Brien, R. Bicknell, S. Fuggle, D. Cranston and A.L. Harris, Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates, J Urol 161 (1999), 799-804.
7. D. Danielpour, Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor beta 1, J Immunol Methods 158 (1993), 17-25.
8. I.E. Eder, A. Stenzl, A. Hobisch, M.V. Cronauer, G. Bartsch and H. Mocker, Transforming growth factors-β1 and β2 in serum and urine from patients with bladder carcinoma, J Urol 156 (1996), 953-957.
9. S. Eissa, S. Kassim and O. El-Ahmady, Detection of bladder tumours: Role ofcytology, morphology-based assays, biochemical and molecular markers, Curr Opin Obstet Gynecol 15 (2003), 395-403.
10. N.G. El-Mawla, M.N. El-Bolkainy and M.H. Khaled, Bladder cancer in Africa: Update, Semin Oncol 28 (2001), 174-178.
11. W. El-Rifai, D. Kamel, M.L. Larramendy, S. Shoman, Y. Gad, S. Baithun, M. El-Awady, S. Eissa, H. Khaled, S. Soloneski, M. Sheaff and S. Knuutila, DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer, Am J Pathol 56 (2000), 871-878.
12. M. Gui, M.A. Idris, Y.E. Shi, A. Muhling and A. Ruppel, Reactivity of Schistosoma japonicum and S. mansom antigen preparations in indirect haemagglutination (IHA) with sera of patients with homologous and heterologous schistosomiasis, Ann Trop Med Parasitol 85 (1991), 599-604.
13. D. Hanahan, A flanking attack on cancer, Nat Med 4 (1998), 13-14.
14. J.A. Hanley and B.J. McNeil, The meaning and use of the area under a receiver operating characteristic (ROC) curve, Radiology 143 (1982), 29-36.
15. S.M. Hyder and G.M. Stancel, Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins, Mol Endocrinol 13 (1999), 806-811.
16. S. Itoh and P. Ten Dijke, Negative regulation of TGF-beta receptor/Smad signal transduction, Curr Opin Cell Biol 19 (2007), 176-184.
17. S.-H. Jeon, S.-J. Lee and S.-G. Chang, Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors, Oncol Rep 8 (2001), 1265-1267.
18. S. Liekens, E. De Clercq and J. Neyts, Angiogenesis: Regulators and clinical applications, Biochem Pharmacol 61 (2001), 253-270.
19. J. Massague, The transforming growth factor-β family, Annu Rev Cell Biol 6 (1990), 597-641.
20. J. Massague, TGF-β signal transduction, Annu Rev Biochem 67 (1998), 753-791.
21. M. Milkiewicz, E. Ispanovic, J.L. Doyle and T.L. Haas, Regulators of angiogenesis and strategies for their therapeutic manipulation, Int J Biochem Cell Biol 38 (2006), 333-357.
22. S. Narayan, T. Thangasamy and R. Balusu, Transforming growth factor-beta receptor signaling in cancer, Front Biosci 10 (2005), 1135-1145.
23. C.A. O'Mahony, D. Albo, G.P. Tuszynski and D.H. Berger, Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells, Surgery 124 (1998), 388-393.
24. G.N. Papanicolaou and V.F. Marshall, Urine sediment smears as a diagnostic procedure in cancers of the urinary tract, Science 101 (1945), 519-520.
25. B. Planz, E. Jochims, T. Deix, H.P. Caspers, G. Jakse and A. Boecking, The role of urinary cytology for detection of bladder cancer, Eur J Surg Oncol 31 (2005), 304-308.
26. M.L. Quek, K. Sanderson, S. Daneshmand and J.P. Stein, New molecular markers for bladder cancer detection, Curr Opin Urol 14 (2004), 259-264.
27. J. Sambrook, E.F. Fritsch and T. Maniatis, Molecular cloning. A laboratory manual, 2nd ed., Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1989, 42-59.
28. Z.M. Shao and M. Nguyen, Angiogenic factors and bladder cancer, Front Biosci 7 (2002), 63-65.
29. L.H. Sobin and C.H. Wittkind, UICC TNM Classification of Malignant Tumors, 5th ed., New York: Wiley Liss, 1997, 187.
30. P.N. Span, N. Grebenchtchikov, J. Geurts-Moespot, J.R. Westphal, A.M. Lucassen and C.G. Sweep, EORTC Receptor and Biomarker Study Group Report: A sandwich enzyme-linked immunosorbent assay forvascular endothelial growth factor in blood and tumor tissue extracts, Int J Biol Markers 15 (2000), 184-191.
31. T. Tammela, B. Enholm, K. Alitalo and K. Paavonen, The biology of vascular endothelial growth factors, Cardiovasc Res 65 (2005), 550-563.
32. B. Tang, M. Vu, T. Booker, S.J. Santner, F.R. Miller, M.R. Anver and L.M. Wakefield, TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression, J Clin Invest 112 (2003), 1116-1124.
33. S. Vosseler, N. Mirancea, P. Bohlen, M.M. Mueller and N.E. Fusenig, Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants, Cancer Res 65 (2005), 1294-1305.
34. J.L. Wrana, L. Attisano, R. Wieser, F. Ventura and J. Massague, Mechanism ofactivation ofthe TGF-β receptor, Nature 370 (1994), 341-347.
35. H.T. Zhang, P. Craft, P.A. Scott, M. Ziche, H.A. Weich, A.L. Harris and R. Bicknell, Enhancement of tumor growth and vascular density by transfection of vascular endothelial growth factor into MCF-7 human breast carcinoma cells, J Natl Cancer Inst 87 (1995), 213-219.